Abstract
Increasing the total dose or the dose intensity of platinum does not improve survival in women with ovarian cancer. High-dose chemotherapy with hematologic support has not been shown to be more effective than standard-dose chemotherapy. Regional dose intensity, through intraperitoneal chemotherapy, may have a role in the treatment of advanced ovarian cancer. Further studies are needed to identify the optimal combination of agents, in addition to a platinum and a taxane, to be used in primary therapy for ovarian cancer.
MeSH terms
-
Anthracyclines / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Cyclophosphamide / administration & dosage
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Dose-Response Relationship, Drug
-
Etoposide / administration & dosage
-
Female
-
Gemcitabine
-
Humans
-
Ovarian Neoplasms / drug therapy*
-
Prognosis
-
Survival Analysis
-
Topotecan / administration & dosage
Substances
-
Anthracyclines
-
Deoxycytidine
-
Etoposide
-
Topotecan
-
Cyclophosphamide
-
Gemcitabine